Rationale: The mechanism of action of diethylcarbamazine (DEC), an antifilarial drug effective against tropical pulmonary eosinophilia, remains controversial. DEC effects on microfilariae depend on inducible NO synthase (iNOS). In eosinophilic pulmonary inflammation, its therapeutic mechanism has not been established. We previously described the rapid up-regulation of bone marrow eosinophilopoiesis in ovalbumin (OVA)-sensitized mice by airway allergen challenge, and further evidenced the down-regulation of eosinophilopoiesis by iNOS-and CD95L-dependent mechanisms. Objectives: We investigated whether: (1) DEC can prevent the effects of airway challenge of sensitized mice on lungs and bone marrow, and (2) its effectiveness depends on iNOS/CD95L. Methods: OVA-sensitized BALB/c mice were intranasally challenged for 3 consecutive days, with DEC administered over a 12-, 3-, or 2-day period, ending at the day of the last challenge. We evaluated: (1) airway resistance, cytokine (IFN-g, IL-4, IL-5, and eotaxin) production, and pulmonary eosinophil accumulation; and (2) bone marrow eosinophil numbers in vivo and eosinophil differentiation ex vivo. Measurements and Main Results: DEC effectively prevented the effects of subsequent challenges on: (1) airway resistance, Th1/Th2 cytokine production, and pulmonary eosinophil accumulation; and (2) eosinophilopoiesis in vivo and ex vivo. Recovery from unprotected challenges included full responses to DEC during renewed challenges. DEC directly suppressed IL-5-dependent eosinophilopoiesis in naive bone marrow. DEC was ineffective in CD95L-deficient gld mice and in mice lacking iNOS activity because of gene targeting or pharmacological blockade. Conclusions: DEC has a strong impact on pulmonary eosinophilic inflammation in allergic mice, as well as on the underlying hemopoietic response, suppressing the eosinophil lineage by an iNOS/ CD95L-dependent mechanism.
The mechanism of action of diethylcarbamazine (DEC), a mainstay of filariasis treatment, remains mysterious despite its continuous worldwide use since 1947. Many studies failed to demonstrate a direct effect of DEC on filarial parasites, which would account for its effectiveness in vivo. It has been proposed that DEC mobilizes a hitherto undefined fast-acting innate immune mechanism (1, 2) . A role for nitric oxide (NO) is suggested by the following: (1) NO is critical for host resistance to filarial infection in mice (3), (2) DEC is reportedly ineffective in mice lacking inducible NO synthase (iNOS) (4) , and (3) lethal reactions to DEC were attributed to systemic release of NO (5) . However, the relationship of DEC effects to NO production by iNOS is difficult to establish in filarial infection models (4) . Importantly, DEC does not promote NO synthesis in the absence of filarial infection (6) .
DEC is effective in tropical pulmonary eosinophilia, a serious complication of filariasis (7) , and beneficial in some patients with asthma (8) . DEC inhibits production of cysteinyl-leukotrienes (CysLT) that are central to asthma pathophysiology (9, 10) . Nevertheless, the mechanisms underlying its beneficial effects in any form of pulmonary eosinophilic inflammation remain unexplored.
We described a prostaglandin E2-activated mechanism for suppression of bone marrow eosinophilopoiesis (11) that requires both iNOS and the ligand (CD95L, FasL, or CD178) for the apoptosis-inducing receptor CD95 (Fas). Because CD95L acts downstream from iNOS in these conditions (11) , evidencing a direction in addition to a dual requirement, we proposed that PGE2 activates an iNOS-CD95L-dependent pathway, further describing its blockade by dexamethasone (11, 12) and CysLT (13) . Because DEC affects both CysLT (9, 10) and NO (4) production, we evaluated its effects on the allergen-induced eosinophilia (14) of bone marrow and lungs observed in ovalbumin (OVA)-sensitized mice after intranasal allergen challenge, which results from strong up-regulation of eosinophilopoiesis (15) . We report that DEC effectively suppresses challenge-induced changes in lungs and bone marrow through a mechanism dependent on both iNOS and CD95L.
METHODS Suppliers
Materials were supplied as follows: FCS and media, Hyclone (Logan, UT); rmIL-5 and cytokine ELISA kits, R&D systems (Minneapolis, MN); DEC, Farmanguinhos (Rio de Janeiro, RJ, Brazil); ovalbumin, ICN Biomedicals (Aurora, OH); phorbol myristate acetate and ionomycin, Calbiochem (San Diego, CA); collagenase, DNAaseI, Percoll, aminoguanidine, monensin, saponin, and protease inhibitor mix (P8340), Sigma (St. Louis, MO); CD4-specific PE-Cy5 and IFN-g-PE antibodies, eBioscience (San Diego, CA).
In Vivo Procedures
Six-to 8-week-old mice of the BALB/c (both wild type and CD95L-deficient gld mutants) and C57BL/6 backgrounds (both wild type and iNOS-deficient knockout mice), from CECAL-FIOCRUZ/RJ, were used following institutionally approved (CEUA#L-010/04, CEUA#L-002/09) protocols, detailed in Figure 1 . Pulmonary function was evaluated 24 hours after the last challenge. Air flow and transpulmonary pressure were recorded in individual mice (17) with a FinePointe RC (Buxco Research System, Wilmington, NC) under anesthesia (Nembutal 60 mg/kg), neuromuscular blockade (bromide pancuronium 1 mg/kg), and mechanical ventilation, after tracheostomy, cannulation, and connection to a pneumotachograph. Mice were exposed to aerosolized methacholine (3-27 mg/ml, for 2.5 min) or PBS after 5 minutes of stabilization. Airway resistance (cm H 2 O/ml/s) and dynamic lung compliance (ml/cm H 2 O) were calculated and digitized per breathing cycle. Increases in enhanced pause (Penh) (18) , were also recorded in conscious, unrestrained mice exposed to methacholine (6-25 mg/ml, for 2.5 min) during 5 minutes, using barometric whole-body plethysmography (Buxco Research System).
Ex Vivo Procedures
Where indicated: (1) peripheral blood was used for total (hemocytometer) and differential (Wright-Giemsa) leukocyte counts; (2) bronchoalveolar lavage fluid (BALF) was collected for total counts, cytocentrifugation, and differential counts; (3) lymphocytes were recovered after digestion of minced lungs for 10 minutes at 378C in 10 ml Iscove Modified Dulbecco's Medium (IMDM) with collagenase (24 mg) and DNAaseI (0.125 mg) and filtration through a cell strainer (Falcon 2360), from the 60 to 75% interface of discontinuous Percoll gradients (19) ; lung and spleen cells from the same animals were further cultured for 5 hours at 2 3 10 6 cells/ml with 20 nM phorbol myristate acetate, 1 mM ionomycin, and 3 mM monensin, before paraformaldehyde (2%) fixation, saponin (0.3%) permeabilization, intracellular staining with CD4-and IFN-g2specific antibodies, and flow cytometric analysis (20) using a FACSCanto II (BDBiosciences Pharmingen, San Diego, CA) gated on lymphocytes for acquisition and Summit V4.3 Build 2445 (Dako do Brasil Ltda., Sã o Paulo, Brazil) for analysis; (4) whole right lung homogenates were prepared in phosphate-buffered saline (PBS) with protease inhibitors, before quantification of total protein and immunoassay for Eotaxin-1, IL-5, and IL-4; (5) lungs were fixed 48 hours in buffered formalin (10%), before automated processing (LEICA TP102), inclusion (LEICA EG1160), sectioning (LEICA RM2155), and hematoxylin and eosin staining; (6) bone marrow cells were collected, counted, and cytocentrifuged before staining for eosinophil peroxidase (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , or further cultured for 7 days at 10 6 /ml in RPMI 1640, 10% FCS, 1 ng/ml rmIL-5, before total and eosinophil peroxidase-positive cell counts, to quantify the impacts of challenge on eosinophilopoiesis in vivo (Day 0, 14) and ex vivo (Day 7, 14), respectively.
Statistical Analysis
Comparisons of pulmonary function data used two-way analysis of variance with the Bonferroni correction (Prism 5 for Windows; GraphPad, La Jolla, CA); all other comparisons used analysis of variance with the Tukey (HSD) correction (Systat for Windows 4; Systat Inc., Evanston, IL).
RESULTS

Effects of DEC on Allergen-Challenged Lungs
To evaluate the impact of DEC on pulmonary function, BALB/c mice submitted to the full sensitization/challenge protocol, as well as the appropriate naive and saline-challenged, sensitized control mice, were either treated for 12 days with DEC or left untreated Figure 1 . In vivo protocols. Black horizontal lines display the sequence of treatments performed in each group; treatments performed in the same day are indicated sequentially from the top down. Solid squares, ovalbumin (OVA) sensitization and boost (100 mg OVA/1.6 mg alum in 0.4 ml saline, subcutaneously, at Days 0 and 14); s, diethylcarbamazine (DEC) (12 mg/kg/d intragastrically, 2 h before challenge, in 0.2 ml dH 2 O) treatment (controls received vehicle); solid triangles, OVA (25 mg in 25 mL saline, intranasally) challenge; solid inverted triangles, saline challenge; X-shaped symbols, aminoguanidine, 4 hours before DEC (50 mg/kg/d, intraperitoneally; Reference 16); solid diamonds, pulmonary function studies and/or euthanasia with tribromoethanol (400 mg/kg, intraperitoneally) followed by sample collection for ex vivo procedures (detailed in METHODS). For the entire study, we used a total of 51 G1 ( Figures 2-8 and examined 24 hours after the last challenge. OVA sensitization/ challenge significantly increased airway resistance in response to 9 and 27 (but not 3) mg/ml methacholine, relative to both control groups ( Figure 2A ). This effect was completely abolished by DEC pretreatment. DEC had no significant effect in either control group. Furthermore, OVA-sensitized/challenged mice also had significantly increased Penh values, relative to controls, in response to 6.25, 12.5, and 25 mg/ml methacholine ( Figure 2B ). The After two-way analysis of variance significant differences were attributable to both the metacholine dose (P , 0.0001) and the group treatments (P , 0.0001). Interactions between dose and treatment were nonsignificant for resistance data (P 5 0.2011) and significant for Penh (P 5 0.0047). The Bonferroni posttest confirmed that DEC pretreatment abolished the effect of allergen challenge at the two higher metacholine concentrations (P , 0.01 and P , 0.001, respectively). (A) n 5 4 (G1, G3, G4, G5); n 5 5 (G2, G6); (B) n 5 4 (G1, G3, G4, G5, G6); n 5 3 (G2). effects of methacholine (at 12.5-25, but not 6.25 mg/ml) were abolished by DEC pretreatment. DEC had no significant effect on either control group.
We next examined DEC effects on cytokines and cytokineproducing cells in lung, and inflammatory leukocytes in BALF and blood. CD4 1 lymphocytes were detectable both in spleen, taken as positive control ( Figure 3A) , and in lungs ( Figure 3B ) of mice from all groups. However, no significant differences were found among these groups for either site. IFN-gproducing lymphocytes (predominantly CD4 2 ) were detectable in spleen ( Figure 3C ) and lungs ( Figure 3D ), but no significant differences were observed among mice submitted to different sensitization/challenge protocols. By contrast, DEC treatment induced a significant increase in IFN-g-producing lymphocyte numbers in the lungs (but not in spleen) of OVA-sensitized/ challenged mice. DEC had no effect on either control group. We further examined the effect of OVA sensitization/challenge on local generation of cytokines that support differentiation (IL-5; Figure 3E ) and migration (Eotaxin-1; Figure 3F ) of eosinophils. Amounts of both cytokines were significantly increased after sensitization/challenge, relative to unchallenged controls. No significant difference was found for either cytokine among the control groups. A similar pattern was observed for the prototypical Th2 cytokine, IL-4 ( Figure 3E ). Importantly, for all three cytokines, DEC treatment of OVA-sensitized/ challenged mice significantly reduced cytokine release relative to untreated controls.
Eosinophil counts in BALF (minimal in control groups) were significantly increased in sensitized/challenged mice ( Figure 4A ). Importantly, this increase was abolished (94.3% reduction) by a full course of DEC. BALF also contained lymphocytes ( Figure  4B ), neutrophils ( Figure 4C ), and mononuclear phagocytes (Figure 4D) . None of these, however, was significantly increased by sensitization/challenge or decreased by DEC. Blood eosinophil counts were significantly increased by sensitization and further increased by challenge ( Figure 4E) ; importantly, DEC abolished the effect of challenge but not that of sensitization ( Figure 4E ). By contrast, blood neutrophil counts were neither increased by sensitization/challenge nor decreased by DEC ( Figure 4F ).
We next analyzed DEC effects on lung histopathology. Lungs from naive ( Figure 5A ) or saline-challenged, sensitized controls ( Figures 5B and 5C ) lacked inflammatory changes, in the absence ( Figure 5B ) or presence ( Figure 5C ) of DEC. By contrast, OVA lungs from sensitized/challenged mice ( Figures  5D, 5F , and 5H) showed extensive inflammatory infiltrates, predominantly in the hilar region ( Figure 5D ). Infiltrates were characteristically observed around bronchi and small-to medium-sized vessels, often bridging several of these structures. Leukocyte plugs were also commonly found inside bronchi ( Figure 5F ). Infiltrates consisted of a mixture of polymorphonuclear leukocytes, including numerous eosinophils (arrows), alongside plasma cells and mononuclear phagocytes ( Figure  5H ). Overall, bronchial epithelium was well preserved. DEC pretreatment of OVA-challenged, sensitized mice (Figures 5E, 5G, and 5I) markedly reduced inflammatory infiltrates ( Figure  5E ), which persisted only as discrete, noncoalescent, peribronchial and perivascular cuffs, composed of numerous neutrophils ( Figure 5I ), with scant eosinophils (arrow).
Together, these observations confirm that DEC suppresses the functional and morphologic abnormalities associated with allergen-induced pulmonary inflammation, especially eosinophilia of peripheral blood, BALF, and lung tissue.
Hemopoietic Impact of DEC
We further evaluated the effects of DEC on allergen-stimulated hemopoiesis in vivo. Sensitization/challenge significantly increased ) and (E-F) peripheral blood were collected for total and differential counts 24 hours after the last challenge. Data are numbers (mean 6 SEM) of (A) eosinophils, (B) lymphocytes, (C) neutrophils, and (D) mononuclear phagocytes in BALF, and of (E) eosinophils and (F) neutrophils in peripheral blood, after each of these sensitization, challenge, and treatment protocols. *P , 0.05; **P , 0.01; ***P , 0.001. For both BALF (A-D) and peripheral blood (E, F), G1, G2, G3, G4, G5, G6. All groups, n 5 3.
eosinophil counts in bone marrow at Day 0, relative to both naive and saline-challenged controls ( Figure 6A ). Importantly, DEC treatment significantly reduced the effect of allergen challenge, but had no effect on unchallenged controls ( Figure 6A ). Eosinophilopoiesis occurring ex vivo in IL-5-stimulated bone marrow cultures was also affected by both challenge and DEC ( Figure 6B ): eosinophil yields at Day 7 were significantly increased by challenge relative to both control groups and were brought back to control levels by DEC pretreatment. Again, DEC had no effect without challenge ( Figure 6B) . Overall, the hemopoietic response to allergen challenge was abolished by DEC. By contrast, DEC had no effect in the absence of challenge. We further evaluated: (1) whether a shorter course of DEC would be as effective, and (2) whether DEC would still work after challenge had been initiated. This was done by starting DEC treatment just before or just after the first challenge (3-and 2-day treatments, respectively). For both in vivo eosinophilopoiesis ( Figure 6C ) and ex vivo responses to IL-5 ( Figure 6D ), a 3-day course of DEC, beginning 2 hours before challenge, was as effective as the full 12-day treatment. By contrast, for both, DEC was ineffective if given after one unprotected challenge ( Figures 6C and 6D) . To determine whether an unprotected allergen challenge round would permanently reduce the effectiveness of DEC, mice were sensitized and challenged with DEC (or vehicle) administration after the last challenge for 7 days, followed by renewed challenge after the last dose of DEC ( Figure  1, G9 and G10 ). For both in vivo ( Figure 6E ) and ex vivo ( Figure  6F ) eosinophilopoiesis, a 7-day course of DEC significantly reduced the effects of the renewed challenge, showing that its effectiveness was not permanently lost as a result of a past, unprotected round of challenge.
iNOS Requirement for DEC Effectiveness in Bone Marrow
We next evaluated whether the effectiveness of DEC in preventing the hemopoietic impact of challenge was dependent on iNOS. This was done by evaluating its effectiveness (1) in iNOSdeficient bone marrow, and (2) in wild-type bone marrow exposed to the selective inhibitor aminoguanidine. The response of C57BL/6 wild-type controls to sensitization and challenge was comparable to that of BALB/c mice, as shown by Day 0 ( Figure 7A ) and Day 7 ( Figure 7D ) eosinophil counts. For both parameters, a full course of DEC prevented the effect of challenge on eosinophilopoiesis (Figures 7A and 7D ). By contrast, even though iNOS-deficient C57BL/6 mice responded as their wild-type controls to sensitization and challenge with respect to Day 0 ( Figure 7B ) and Day 7 ( Figure 7E ) eosinophil counts, this response was not abolished by DEC: eosinophil counts of DEC-treated, OVA-sensitized/challenged mice lacking iNOS remained significantly different from those of unchallenged controls (P 5 0.031 and P 5 0.049, respectively, for Figures 7B and 7E) . We next examined whether DEC would directly suppress eosinophilopoiesis in bone marrow culture through an iNOS-dependent mechanism. Eosinophilopoiesis in bone marrow cultures from wild-type C57BL/6 control mice was inhibited significantly and dose-dependently by DEC ( Figure  7C ). By contrast, bone marrow from iNOS-deficient mice was fully resistant to DEC in the same conditions ( Figure 7F ).
We further examined whether aminoguanidine would block the in vivo effects of DEC on allergen-stimulated eosinophilopoiesis ( Figure 7G ). Aminoguanidine could effectively block DEC effects on bone marrow, provided it was administered before (fourth column, G12 in Figure 1 ) DEC during the challenge period (for BALB/c control mice treated with DEC in the absence of aminoguanidine; see Figure 6C ). By contrast, if aminoguanidine was first administered when DEC treatment had already been initiated, DEC remained fully effective (third column, G11 in Figure 1 ), even though aminoguanidine still preceded DEC during the challenge period. This shows that DEC was pharmacologically active in vivo, before both aminoguanidine and challenge. DEC (10 26 M) also decreased significantly eosinophil yield in naive BALB/c bone marrow, if present over a 7-day culture period (Figure 7H ). This effect was totally prevented by aminoguanidine, 10 24 M. Aminoguanidine had no detectable effect in the absence of DEC. Finally, we evaluated whether an unprotected challenge of a sensitized donor would affect the subsequent responses of its bone marrow to DEC in culture ( Figure 7I ). Bone marrow from sensitized/challenged mice did not respond to DEC in vitro at all, even though it showed, as expected, significantly increased responses to IL-5 relative to naive controls, unlike bone marrow from naive mice, which was sensitive to DEC in vitro.
Requirement for CD95L
Because we previously showed that eosinophilopoiesis was regulated by a mechanism requiring both iNOS and CD95L, acting in sequence (11), we examined whether DEC effectiveness, in vivo and in vitro, would also be affected by the gld mutation, which abolishes CD95L function. Gld mice responded to sensitization and challenge like wild-type BALB/c controls, both with respect to Day 0 ( Figure 8A ) and Day 7 ( Figure 8B ) counts. Importantly, however, they showed no significant responses to DEC treatment, and eosinophil counts remained significantly different from those of unchallenged controls (P 5 0.001 and P 5 0.012, respectively). In vitro, direct effects of DEC (10 26 -10 28 M) on eosinophilopoiesis were very significant in naive wild-type control mice ( Figure 8C ) but undetectable in gld mutants ( Figure 8D ). Finally, we examined whether DEC Figure 1) . (E, F) Effect of a 7-day course of DEC on (E) in vivo and (F ) ex vivo bone marrow eosinophil counts of mice previously submitted to an unprotected round of challenges (G9, G10 in Figure 1 ). *P , 0.05; **P , 0.01; ***P , 0.001. All groups, n 5 3.
had any effect on eosinophil infiltration of the lungs in CD95L-deficient mice. Eosinophil-rich pulmonary infiltrates were present in sensitized and challenged gld mice ( Figure 8E ). Marked infiltration persisted after a full course of DEC ( Figure 8F ), sharply contrasting with the response of BALB/c controls ( Figures 5F and 5G) .
DISCUSSION
This study provides the first evidence of a therapeutic mechanism for DEC in any model of eosinophilic pulmonary inflammation. DEC, used in a regimen that kills microfilariae and adult worms in chronic filariasis patients (22) and, over longer periods, cures tropical pulmonary eosinophilia (7), was effective against allergic pulmonary inflammation and the associated increases in airway resistance, cytokine production, and eosinophil numbers. DEC acted in short-term prophylaxis, but was not curative. Together, its actions were clearly beneficial in this experimental model. DEC was markedly selective for the eosinophil lineage, reducing eosinophil counts in BALF and blood, eosinophil infiltration of interstitium and bronchoalveolar spaces, generation of cytokines involved in eosinophil production, activation, and migration, and challenge-induced increases in eosinophilopoiesis, with no effect on other leukocyte types. Measurements of airway resistance confirmed significant increases in OVA-sensitized/challenged mice, which were prevented by DEC. Although these changes were closely paralleled by changes in eosinophilia (23, 24) , this does not establish a causal relationship. Indeed, DEC had additional effects, especially on cytokine expression, which had no obligatory relation to eosinophils.
Although DEC had no effect on CD4 1 (Th) cell numbers, it significantly increased IFN-g-producing lymphocyte numbers in lungs, which were not classical CD4 1 Th1 cells, possibly representing either CD8 1 T lymphocytes or natural killer cells, both well-established sources of IFN-g (25) . DEC also significantly suppressed IL-4, IL-5, and eotaxin production. Overall, DEC-induced shifts in cytokine production within challenged lungs were unfavorable to eosinophilic infiltration. The possible contribution of IFN-g-producing lymphocytes to iNOS induction, however, remains open for future evaluation.
The following supports the view that the iNOS-CD95L pathway mediates these selective effects of DEC on the eosinophil lineage: (1) effects in vivo and in vitro were blocked by genetic and pharmacological inactivation of iNOS, (2) effects on lungs and bone marrow required CD95L, and (3) effects in vivo and in vitro were mechanistically interrelated, as shown by the abolition of DEC effectiveness in both settings by one single unprotected challenge.
Every in vivo effect of DEC reported here was observed after sensitization and challenge. One single unprotected challenge, however, abolished the effectiveness of DEC on bone marrow (in vivo, ex vivo, and in vitro). This indicates that DEC must be present before challenge to act, but becomes ineffective if introduced soon after the first challenge. DEC acted rapidly in our model, as shown by: (1) its effectiveness in a 3-day regimen started a few hours before challenge; and (2) by aminoguanidine blockade, effective only if started before DEC was introduced. In filarial infection, DEC acted unusually fast (4). Therefore, timing of DEC relative to challenge was critical for its action in vivo. By contrast, challenge was not required in vitro: in IL-5-stimulated bone marrow cultures from naive donors, DEC effectively suppressed eosinophilopoiesis through a mechanism requiring iNOS and CD95L. Hence, in the presence of IL-5 in vitro, iNOS and CD95L play critical roles in bone marrow responses to DEC, consistent with evidence of their expression (11, and unpublished observations), independently of sensitization/challenge. Importantly, this in vitro effect still required DEC to be present, because bone marrow from DEC-treated naive mice, further cultured with IL-5 without DEC, was not suppressed. These apparently distinct in vitro and in vivo requirements are possibly reconciled by the observation that the effectiveness of IL-5, the major eosinophilopoiesispromoting cytokine, is enhanced by challenge, leading to increased expansion of eosinophil precursors in response to IL-5, despite unchanged IL-5 concentrations (15) . Eosinophil precursors recently stimulated by IL-5 are found both in vitro and in vivo (14) , when DEC is effective. Accordingly, challenge simply provides the opportunity for DEC to act in vivo on these targets ( Figure 6A ), suppressing their expansion, provided it was present during the initial 24 hours ( Figure 6D ). Alternatively, if stimulated after unprotected challenge, the targets would expand and mature into DEC-resistant eosinophils within 24 hours ( Figure 6D ). Loss of responsiveness to PGE2, the prototypical activator of the iNOS-CD95L pathway, during maturation is observed in IL-5 stimulated cultures (11, 12) . It remains to be established whether DEC, like PGE2, enhances CD95L expression (11) .
Our findings may contradict the view that DEC, as an effective antiparasitic agent, should boost eosinophil effector function. None of the many antihelminthic drugs currently used acts exclusively, or predominantly, through eosinophils (26, 27) . Eosinophil infiltrates surrounding dead filariae were only described long after DEC treatment and drug elimination (22) . Regardless of the impact of eosinophil participation, our findings should prompt evaluation of the role of CD95L in the antifilarial effects of DEC, because a dual dependence on iNOS and CD95L represents a substantial departure from previous views on this issue (4).
